StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Friday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE BTX opened at $2.24 on Friday. The business’s 50 day moving average price is $2.14 and its 200-day moving average price is $1.81. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10. The company has a market cap of $131.77 million, a price-to-earnings ratio of -0.99 and a beta of 4.61.

Hedge Funds Weigh In On Brooklyn ImmunoTherapeutics

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC grew its holdings in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned approximately 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent reporting period. 26.00% of the stock is currently owned by hedge funds and other institutional investors.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.